Skip to main content
Premium Trial:

Request an Annual Quote

Epistem Hoping to Apply 'Plucked Hair' Biomarker Approach to Cancer Drug Studies

NEW YORK (GenomeWeb News) – British biotech firm Epistem has completed a preliminary study of its plucked hair biomarker technology with AstraZeneca, the company announced today.
 
The minimally invasive hair biomarker system makes it possible to retrieve RNA from the base of a single, plucked human hair, facilitating gene expression measurements.
 
Results from the current study suggest the plucked-hair method is not only well tolerated by patients, but also provides reliable results. The researchers were able to evaluate RNA — representing over 13,000 genes — from more than 85 percent of the single hairs. The results were presented at a recent AACR-NCI-EORTC meeting in San Francisco.
 
By comparing the gene sets linked to tumors as well as drug exposure and toxicity, the companies hope to eventually use the hair biomarker approach to evaluate the effectiveness of new cancer treatments.
 
“Our published results clearly demonstrate that the method is both feasible and practical, and offers the promise of providing insights into both dose and patient selection,” Andrew Hughes, an AstraZeneca scientist, said in a statement.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.